Skip to main content
. Author manuscript; available in PMC: 2015 Sep 28.
Published in final edited form as: J Control Release. 2014 Jun 28;190:314–330. doi: 10.1016/j.jconrel.2014.06.028

Table 4.

ELP-functionalized hybrid drug delivery systems

Application ELP sequence Functionalization Ref
ELP-functionalized plasmonic nanoparticles (VPGXG)180 X=V5G3A2 Lysine residue (and N-terminal amine) for electrostatic adsorption or covalent grafting to MUA-functionalized gold nanoparticles [109, 110]
[VG-(VPGVG)4-VPG]8-[VG-(VPGVG)2-VPGCG-VPGVG-VPG]2 Cysteine residues for functionalization of gold nanorods through gold thiol bonds [111]
[VG-(VPGVG)4-VPG]8-[VG-(VPGVG)2-VPGCG-VPGVG-VPG]8 or 12 Cysteine residues for functionalization of gold nanorods and cross-linking of composite matrices with physical encapsulation of 17-AAG drug [112]
ELP-functionalized liposomes (VPGVG)3 Stearyl group functionalization for incorporation into bilayer of doxorubicin-encapsulating PEGylated liposomes and cyclic RGD-decorated doxorubicin-encapsulating PEGylated liposomes [113, 114]
ELP-functionalized dendrimers (VPGVG)1 Boc-functionalization for conjugation of ELP C-terminus to amines on PAMAM dendrimers with physical encapsulation of model drug rose bengal [115]